<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="448">
  <stage>Registered</stage>
  <submitdate>6/05/2004</submitdate>
  <approvaldate>6/05/2004</approvaldate>
  <nctid>NCT00082381</nctid>
  <trial_identification>
    <studytitle>Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin</studytitle>
    <scientifictitle>Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>H8O-MC-GWAA</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes Mellitus, Type 2</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Exenatide (AC2993)
Treatment: drugs - Insulin glargine

Experimental: Exenatide Arm - exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks

Active Comparator: Insulin Glargine Arm - subcutaneous injection, once daily; forced titration to target blood glucose level


Treatment: drugs: Exenatide (AC2993)
subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks

Treatment: drugs: Insulin glargine
subcutaneous injection, once daily; forced titration to target blood glucose level

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in Glycosylated Hemoglobin (HbA1c) - Change in HbA1c from baseline to week 26</outcome>
      <timepoint>Baseline, week 26</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients Achieving HbA1c &lt;=7% - Percentage of patients in each arm who had HbA1c &gt;7% at baseline and had HbA1c &lt;=7% at week 26 (percentage = [number of subjects with HbA1c &lt;=7% at week 26 divided by number of subjects with HbA1c &gt;7% at baseline] * 100%).</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Body Weight - Change in body weight from baseline to week 26</outcome>
      <timepoint>Baseline, week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Fasting Serum Glucose - Change in fasting serum glucose from baseline to week 26</outcome>
      <timepoint>Baseline, week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in 7-point Self-monitored Blood Glucose (SMBG) Profile - Change in 7-point (pre-breakfast, 2 hour post breakfast, pre-lunch, 2 hour post lunch, pre-dinner, 2 hour post dinner, 0300 hours) SMBG profile from baseline to week 26</outcome>
      <timepoint>Baseline, week 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Patients With Hypoglycemic Events - Percentage of patients who experienced at least one episode of hypoglycemia at any point during the 26 week Parent Study (incidence of hypoglycemia = number of patients who experienced at least one episode of hypoglycemia at any point during the 26 week Parent Study divided by the total number of patients who participated in the 26 week Parent Study</outcome>
      <timepoint>26 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Rate of Hypoglycemic Events - Change in rate of hypoglycemic events per 30 days per patient from baseline to week 26</outcome>
      <timepoint>Baseline, week 26</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients have been treated with a stable dose of one of the following for at least 3
             months prior to screening: 1. 1500 to 2550 mg/day immediate-release metformin (or 1500
             to 2000 mg/day extended-release metformin) and at least an optimally effective dose of
             a sulfonylurea, or 2. a fixed-dose sulfonylurea/metformin combination therapy with the
             same sulfonylurea and metformin requirements as for the individual components.

          -  HbA1c between 7.0% and 10.0%, inclusive.

          -  History of stable body weight (not varying by &gt;10% for at least three months prior to
             screening).

          -  Female patients are not breastfeeding, and female patients of childbearing potential
             (not surgically sterilized and between menarche and 1-year postmenopause)</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients are investigator site personnel directly affiliated with the study, or are
             immediate family of investigator site personnel directly affiliated with the study.

          -  Patients are employed by Lilly or Amylin.

          -  Patients have participated in this study previously or any other study using AC2993 or
             GLP-1 analogs.

          -  Patients have participated in an interventional medical, surgical, or pharmaceutical
             study within 30 days prior to screening. This criterion includes drugs that have not
             received regulatory approval for any indication at the time of study entry.

          -  Patients have had greater than three episodes of severe hypoglycemia within 6 months
             prior to screening.

          -  Patients are undergoing therapy for a malignancy, other than basal cell or squamous
             cell skin cancer.

          -  Patients have cardiac disease that is Class III or IV, according to the New York Heart
             Association criteria.

          -  Patients have a known allergy or hypersensitivity to insulin glargine, AC2993, or
             excipients contained in these agents.

          -  Patients have characteristics contraindicating metformin or sulfonylurea use,
             according to product-specific label, in the opinion of the investigator.

          -  Patients have a history of renal transplantation or are currently receiving renal
             dialysis or have serum creatinine &gt;=1.5 mg/dL for males and &gt;=1.3 mg/dL for females.

          -  Patients have obvious clinical signs or symptoms of liver disease, acute or chronic
             hepatitis, or alanine aminotransferase/serum glutamicpyruvic transaminase greater than
             three times the upper limit of the reference range.

          -  Patients have known hemoglobinopathy or chronic anemia.

          -  Patients are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid
             therapy (excluding topical and inhaled preparations) or have received such therapy
             within 2 weeks immediately prior to screening.

          -  Patients have used any prescription drug to promote weight loss within 3 months prior
             to screening.

          -  Patients have any other condition (including known drug or alcohol abuse or
             psychiatric disorder) that precludes them from following and completing the protocol,
             in the opinion of the investigator.

          -  Patients fail to satisfy the investigator of suitability to participate for any other
             reason.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>551</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Australian Clinical Research Centre - Miranda</hospital>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <hospital>Clinical Trial and Research Unit - Wollongong</hospital>
    <hospital>Royal Brisbane Hospital - Brisbane</hospital>
    <hospital>Royal Adelaid Hospital - Adelaid</hospital>
    <hospital>Repatriation General Hospital - Daw Park</hospital>
    <hospital>SA Endocrine Clinical Research - Keswick</hospital>
    <hospital>Eastern Health (Box Hill Hospital) - Box Hill</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Freemantle Hospital - Freemantle</hospital>
    <postcode>2228 - Miranda</postcode>
    <postcode>2065 - St. Leonards</postcode>
    <postcode>2500 - Wollongong</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>5000 - Adelaid</postcode>
    <postcode>5041 - Daw Park</postcode>
    <postcode>5035 - Keswick</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode> - Freemantle</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Endegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Merksem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Sint Gillis Waas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Curitiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Fortaleza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Porto Alegre</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Jyvaskyla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aschaffenburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bosenheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dortmund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Homburg/Saar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neuss</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Neuwied</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Bilthoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Brunssum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nieuwegein</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Stadskanaal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Westeinde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Jessheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Rud</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Stravanger</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Czestochowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Mielec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Almada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Bayamon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Manati</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ponce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Rio Piedras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Yabucoa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Goteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Helsingborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Eli Lilly and Company</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial
      to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as
      measured by hemoglobin A1c (HbA1c).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00082381</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Chief Medical Officer, MD</name>
      <address>Eli Lilly and Company</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>